These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7651970)

  • 1. Dry-powder inhalers: evaluation of testing methodology and effect of inhaler design.
    Broadhead J; Rouan SK; Rhodes CT
    Pharm Acta Helv; 1995 Jul; 70(2):125-31. PubMed ID: 7651970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
    Nolan LM; Li J; Tajber L; Corrigan OI; Healy AM
    Int J Pharm; 2011 Feb; 405(1-2):36-46. PubMed ID: 21129460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and evaluation of insulin dry powder for inhalation.
    Mahesh Kumar T; Misra A
    Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
    Lucas P; Anderson K; Staniforth JN
    Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
    Taki M; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2010 Mar; 388(1-2):40-51. PubMed ID: 20026261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
    Kaewjan K; Srichana T
    Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates.
    Chrystyn H
    Respir Med; 2003 Feb; 97(2):181-7. PubMed ID: 12587970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The match between adhesive mixture powder formulations for inhalation and the inhaler device.
    Thalberg K; Ahmadi R; Stuckel J; Elfman P; Svensson M
    Eur J Pharm Sci; 2023 Jul; 186():106457. PubMed ID: 37116546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.
    Smith KJ; Chan HK; Brown KF
    J Aerosol Med; 1998; 11(4):231-45. PubMed ID: 10346666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved respirable fraction of budesonide powder for dry powder inhaler formulations produced by advanced supercritical CO
    Miyazaki Y; Aruga N; Kadota K; Tozuka Y; Takeuchi H
    Int J Pharm; 2017 Aug; 528(1-2):118-126. PubMed ID: 28583335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can patients use all dry powder inhalers equally well?
    Gustafsson P; Taylor A; Zanen P; Chrystyn H
    Int J Clin Pract Suppl; 2005 Dec; (149):13-8. PubMed ID: 16279998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.